BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,895,464 | $8,226,533 | $6,573,313 | $5,198,163 |
| - Cash | $642,951 | $749,402 | $540,599 | $681,101 |
| + Debt | $8,721 | $2,677,137 | $1,858,248 | $1,730,584 |
| Enterprise Value | $9,261,234 | $10,154,268 | $7,890,962 | $6,247,646 |
| Revenue | $120,700 | $110,565 | $116,633 | $5,882 |
| % Growth | 9.2% | -5.2% | 1,882.9% | – |
| Gross Profit | $114,137 | $106,912 | $113,994 | $3,798 |
| % Margin | 94.6% | 96.7% | 97.7% | 64.6% |
| EBITDA | -$173,345 | -$142,704 | -$126,183 | -$235,048 |
| % Margin | -143.6% | -129.1% | -108.2% | -3,996.1% |
| Net Income | -$182,743 | -$181,903 | -$167,422 | -$265,050 |
| % Margin | -151.4% | -164.5% | -143.5% | -4,506.1% |
| EPS Diluted | -0.96 | -0.95 | -0.88 | -1.4 |
| % Growth | -1.1% | -8% | 37.1% | – |
| Operating Cash Flow | -$109,574 | -$80,681 | -$199,235 | -$195,326 |
| Capital Expenditures | -$470 | -$5,094 | -$1,595 | -$3,237 |
| Free Cash Flow | -$110,044 | -$85,775 | -$200,830 | -$198,563 |